Research programme: Gram negative infection therapeutics - Nosopharm

Drug Profile

Research programme: Gram negative infection therapeutics - Nosopharm

Alternative Names: NOSO 95; NOSO 95179; NOSO 95400

Latest Information Update: 13 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nosopharm
  • Class
  • Mechanism of Action Bacterial growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 07 Dec 2015 Nosopharm plans a phase I trial for Gram-negative infections
  • 03 Sep 2014 Preclinical trials in Gram-negative infections in France (unspecified route)
  • 31 Mar 2013 Early research in Gram-negative infections in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top